Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002337 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
A Phase 1 study, sponsored by Otsuka America Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00002337: Completed Phase 1 study, sponsored by Otsuka America Pharmaceutical.
NCT00002337 is a Phase 1 study that has completed, run by Otsuka America Pharmaceutical. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002337, a Phase 1 study, has completed, sponsored by Otsuka America Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Interventions
- DRUG Vesnarinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Phase | Phase 1 |
What the finished NCT00002337 record still lists
NCT00002337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Vesnarinone is the first listed.
NCT00002337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002337 about?
NCT00002337 is a clinical study titled "A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease". To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
What is the current status of trial NCT00002337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants.
What interventions are being tested in trial NCT00002337?
The interventions under investigation include: Vesnarinone (DRUG).
Who is sponsoring clinical trial NCT00002337?
This trial is sponsored by Otsuka America Pharmaceutical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002337's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management